Antenatal screening for HIV, hepatitis B and syphilis in the Netherlands is effective by Op de Coul, Eline LM et al.
RESEARCH ARTICLE Open Access
Antenatal screening for HIV, hepatitis B and
syphilis in the Netherlands is effective
Eline LM Op de Coul
1*, Susan Hahné
1, Yolanda WM van Weert
1, Petra Oomen
1, Colette Smit
2,
Kitty PB van der Ploeg
3, Daan W Notermans
4, Kees Boer
5 and Marianne AB van der Sande
1
Abstract
Background: A screening programme for pregnant women has been in place since the 1950s in the Netherlands.
In 2004 universal HIV screening according to opting out was implemented. Here, we describe the evaluation of the
effectiveness of antenatal screening in the Netherlands for 2006-2008 for HIV, hepatitis B virus (HBV) and syphilis in
preventing mother-to-child transmission, by using various data sources.
Methods: The results of antenatal screening (2006-2008) were compared with data from pregnant women and
newborns from other data sources.
Results: Each year, around 185,000 pregnant women were screened for HIV, HBV and syphilis. Refusal rates for the
screening tests were low, and were highest (0.2%) for HIV. The estimated annual prevalence of HIV among
pregnant women was 0.05%.
Prior to the introduction of screening, 5-10 children were born with HIV annually After the introduction of
screening in 2004, only 4 children were born with HIV (an average of 1 per year). Two of these mothers had
become pregnant prior to 2004; the third mother was HIV negative at screening and probably became infected
after screening; the fourth mother’s background was unknown. Congenital syphilis was diagnosed in fewer than 5
newborns annually and 5 children were infected with HBV. In 3 of these, the mothers were HBeAg positive (a
marker for high infectivity). We estimated that 5-10 HIV, 50-75 HBV and 10 syphilis cases in newborns had been
prevented annually as a result of screening.
Conclusions: The screening programme was effective in detecting HIV, HBV and syphilis in pregnant women and
in preventing transmission to the child. Since the introduction of the HIV screening the number of children born
with HIV has fallen dramatically.
Previous publication: [Translation from: ‘Prenatale screening op hiv, hepatitis B en syphilis in Nederland effectief’,
published in ‘The Dutch Journal of Medicine’ (NTVG, in Dutch)]
Background
[Translation from: ‘Prenatale screening op hiv, hepatitis
B en syphilis in Nederland effectief’, first published in
‘The Dutch Journal of Medicine ‘ by Op de Coul EL,
v a nW e e r tJ W ,O o m e nP J ,S m i tC ,H a h n éS J ,N o t e r -
mans DW, Van der Sande MA: Ned Tijdschr Geneeskd
2010, 154: A2175 [1]
A screening programme for pregnant women has been
in place since the 1950s in the Netherlands. Initially the
programme exclusively consisted of determining the
ABO blood group and detecting syphilis antibodies. In
the 1970s, the Rhesus (D) factor was added. To this
were added, the hepatitis B (HBV) carrier test in 1989,
the irregular erythrocytes antibodies (IEA) test in 1998
and in 2004 the HIV antibody test.
The blood sample is collected during the first midwife
appointment (preferably before the 13th week of the preg-
nancy) according to the opting-out principle, whereby all
pregnant women undergo the test after having been pro-
vided with information, unless they explicitly state they do
not wish to participate. * Correspondence: eline.op.de.coul@rivm.nl
1Centre for Infectious Disease Control, National Institute for Public Health
and the Environment, Bilthoven, the Netherlands
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result for one or more infectious diseases during and/or
after the pregnancy in order to limit the risk of congeni-
tal (intra-uterine) and perinatal infections (around the
pregnancy) to the child [2,3]. Virtually all pregnant
women in the Netherlands participate in this infectious
diseases screening programme [4,5].
We examined the effectiveness of HIV, HBV and syphi-
lis screening in 2006-2008. We investigated how many
pregnant women and newborns were infected with HIV,
HBV, or syphilis and how many congenital/perinatal
infections were prevented through timely interventions
(immunisation of the child, e.g. HBV) or treatment of the
mother (HIV, syphilis).
Methods
Since 2005, the screening results from pregnant women
have been collected in a national electronic database
(Praeventis). Details on participation and screening results
are collected by regional coordination programmes (RCP)
by midwifes and regional laboratories. If the result of the
first screening test is abnormal then other tests are carried
out for confirmation. The HIV diagnosis is based on an
ELISA, followed by an immunoblot or RNA test. HBsAg is
determined for HBV followed by a confirmatory HBsAg
test and tests for HBeAg (marker for high infectivity), anti-
HBc and anti-Hbe (marker for low infectivity). Syphilis is
determined using TPHA/TPPA (Treponema pallidum
haemagglutination, T. pallidum particle agglutination)
tests followed by a ‘venereal disease research laboratory’
(VDRL)-test and/or a fluorescent treponemal antibody
(FTA) absorption test.
To determine the prevalence, all confirmed positive
results were counted, regardless of the type test.
Prior to the impact evaluation, various process evalua-
tions of the screening programme were conducted. These
showed that registration of the confirmatory tests follow-
ing an abnormal initial blood test was incomplete [4,6].
The results of these tests were not provided unambiguous
by laboratories which meant that the definitive test result
(positive or negative HIV, HBV or syphilis status) was
often not clear. For this reason, the missing confirmatory
results and conclusions from 2006-2008 were requested
from laboratories. Of the 212 missing HIV confirmatory
results, 44 (21%) were retrieved (17 positive and 27 nega-
tive). Of the 404 missing syphilis results, 74 were retrieved
(18%; 48 positive, 26 negative) and of the 160 missing
HBV results 47 (29%; 35 positive and 12 negative). Unfor-
tunately, it was not possible to retrieve all definitive
results. Therefore the prevalence of infectious diseases was
estimated in three ways: (1) as minimum prevalence: the
number of confirmed positive test results in pregnancies
divided by the total number of pregnancies screened; (2)
under the assumption that pregnant women with a
positive result at the initial blood test, but no confirma-
tion, were equally likely to have had a positive result as
those pregnant women who have had confirmation; (3)
under the assumption that all pregnant women without a
confirmatory result were positive cases (maximum
prevalence).
The effectiveness of screening for HIV, syphilis and HBV
was calculated on the basis of the prevention of these infec-
tions in pregnant women and newborns. For this calcula-
tion Praeventis data were compared with other data
sources (Dutch National Medical Register - Landelijke
Medische Registratie (LMR), RIVM-LIS (Laboratory for
Infectious Diseases and Perinatal Screening - Laboratorium
voor Infectieziekten en Screening) and Osiris (compulsory
notification of infectious diseases)). We compared the
number of pregnant women screened, women refusing to
be tested and results, and the demographic characteristics
of the women with a positive test result, where available.
For each disease, the contribution of these data sources
w a sa sf o l l o w s .
HIV
No distinction is made in Praeventis between newly diag-
nosed HIV and known HIV infected. Therefore, these data
were obtained from the ‘Stichting HIV Monitoring’
(SHM), including HIV test results from newborns [7].
Hepatitis B
The RIVM evaluates the HBV vaccination programme for
children of HBsAg positive mothers [8,9]. Data from this
evaluation were compared with the HBsAg and/or HBeAg
positive results from pregnant women registered in Prae-
ventis. An estimate of the number of known versus new
HBV positive mothers was made based on a comparison
of HBV positive pregnant women in Osiris (newly diag-
nosed) and Praeventis.
Syphilis
Compulsory notification of syphilis came to an end in
1999 and since then there has been no nationwide regis-
tration system for monitoring of congenital syphilis (CS).
Two alternative data sources were investigated in order to
acquire an insight into the number of CS cases in the
Netherlands. The RIVM performs IgM serodiagnostics in
neonates and young children (<1 year) who are suspected
of having CS [10]. In addition, CS-related hospital admis-
sions from LMR were also analysed.
Results
Results of pregnancy screening
In 2008 a blood test was offered to 190,141 pregnant
women. In 2007 and 2006 the numbers were 186,141
and 185,942 respectively (table 1). HBV and syphilis
tests were refused 1 to 4 times per year only. Frequency
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Page 2 of 7of refusal for the HIV test was higher: 376 times in
2008, 350 in 2007 and 340 in 2006 (0.2%).
Annually between 70 to 90 women were confirmed
HIV positive. These refer to the minimum numbers of
HIV infections given that the HIV-confirmation was not
available for everybody (3-21% unknown).
HIV prevalence was estimated to be between 0.04 and
0.08% in 2008 and was stable during the study period
(table 1). False-positive HIV results occurred regularly;
only 24-27% of women with a positive ELISA result also
had a positive confirmation.
HBsAg-prevalence could be determined more accu-
rately as few confirmatory results were missing (2-4%)
and was estimated at 0.33% in 2008, which was a
decline compared to 2006 (0.38-0.40%, c2t e s t ,p=
0.002). Prevalence of syphilis was between 0.10 and
0.17%, which was an increase compared to 2006 (0.08-
0.13%, p = 0.02).
For hepatitis B, the confirmatory test was also positive
for 65%-74% of women with an initial positive test. For
syphilis these percentages ranged between 44 and 55%
(table 1).
Pregnant women with a positive blood test
The numbers of pregnant women with HIV in care were
66 (2008), 78 (2007) and 67 (2006) (source: SHM). In
Praeventis, 68 (2008), 90 (2007) and 81 (2006) women
were registered with HIV. From the SHM registration it
appeared that 40% of these women were diagnosed with
HIV for the first time during pregnancy (Figure 1, 2008
incomplete, not shown).
The majority of women originated from countries
with a generalised HIV epidemic (2007: 67%, mainly
sub-Saharan Africa). Relatively more Western women
were newly diagnosed after the HIV screening was
introduced in 2004: 5-10 per year. In the period prior
to 2004 between 0-4 were diagnosed per year (c2, p =
0.01) (Figure 2 & 3).
Virtually all HBV infections involved pregnant women
who are long-term carriers (2008: 99.2%). The most fre-
quently reported regions of origin were: Asia (38%),
sub-Saharan Africa (23%), Middle East (17%), Eastern
and Central Europe (12%), Mid- and South America
(5%) and other (5%).
HIV, HBV and syphilis infections in newborns
The number of children born with HIV dropped from 9
in 2002 to 0 in 2008. After the introduction of screening
in 2004, four children were born with HIV (Figure 1).
Two mothers became pregnant before screening was
introduced. One mother was HIV negative and probably
became infected with HIV after the 12th week of preg-
nancy. The four children all had at least one parent not
born in the Netherlands. No additional information was
available for the fourth mother.
T h e r ew e r en ok n o w nc a s e so fm o t h e r - t o - c h i l dt r a n s -
mission by HIV infected women being treated with anti-
retroviral therapy [7].
Five children were born with HBV between 2006-2008
(table 2). In three of these the mothers were HBeAg
positive (a marker for high infectivity). Three mothers
originated from China. All five children were immunised
Table 1 Results of blood tests for hiv, HBV and syphilis, 2006-2008
Year Number
refusers
(%)
Number
pregnancies
tested
Result
positive
12
weeks*
Number with
confirmatory
Result (%)
Result
confirmed
positives
(%)**
Result
negative
Total
Prevalence
estimate 1
(minimum)
Prevalence
estimate 2
Prevalence
estimate 3
(maximum)
95% CI
(based on
confirmed
positives)
HIV
2006 340 (0.2) 185.602 342 274 (80%) 81 (24%) 184.188 0.04 0.05 0.08 0.04 - 0.05
2007 350 (0.2) 185.791 327 316 (97%) 90 (27%) 183.884 0.05 0.05 0.05 0.04 - 0.06
2008 376 (0.2) 189.765 289 229 (79%) 68 (24%) 188.430 0.04 0.05 0.07 0.03 - 0.05
HBV
2006 1
(<0.001)
185.941 966 927 (96%) 714 (74%) 184.621 0.38 0.40 0.40 0.36 - 0.41
2007 4 (<0.01) 186.137 868 848 (98%) 620 (71%) 185.015 0.33 0.34 0.34 0.31 - 0.36
2008 1
(<0.001)
190.140 932 896 (96%) 605 (65%) 189.771 0.32 0.33 0.33 0.29 - 0.34
Syphilis
2006 1
(<0.001)
185.941 320 215 (67%) 142 (44%) 184.181 0.08 0.12 0.13 0.06 - 0.09
2007 4 (<0.01) 186.137 331 231 (70%) 181 (55%) 185.719 0.10 0.14 0.15 0.08 - 0.11
2008 2
(<0.001)
190.139 359 241 (67%) 197 (55%) 189.447 0.10 0.16 0.17 0.09 - 0.12
Excludes pregnancies not carried to term (spontaneous or through surgical abortion). HBV: 15 (2008), 22 (2007), 22 (2006); HIV: 1 (2008), 0 (2007), 1 (2006);
syphilis: 1 (2008), 1 (2007), 3 (2006).
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Page 3 of 7in time with the HBIg and HBV vaccine. Information
regarding the mother’s treatment or viral load was not
registered.
Congenital syphilis was diagnosed in fewer than 5
newborns per year by the RIVM in the last ten years
(Table 2, Figure 4). In all cases where newborns were
infected, the mothers belonged to vulnerable groups;
primarily untreated mothers (illegal immigrants or drug-
users) who had withdrawn from regular pregnancy mon-
itoring [6].
Prevented peri-/congenital infections per year
Table 2 demonstrates the number of infections in new-
borns per year (January - December) in relation to the
number of pregnant women in the previous six-month
period (June-June, screening occurs approximately six
months prior to birth).
We estimated the number of children who would have
been exposed had there been no pregnancy screening or
treatment. The number of peri-/congenital infections
was calculated on the basis of an estimate of the num-
ber of pregnant women with confirmed HIV and HBV
(both 40% of all screen positive pregnancies) discovered
annually through the screening programme, the number
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Page 4 of 7of active syphilis infections (17%) in pregnant women
with a syphilis positive result and the average risk of
transmission from mother to child (HIV/HBV: 20-30%;
active syphilis: 50%) (table 2) [6,11,12]. We estimated
that 5-10 HIV, 50-75 HBV and 10 syphilis cases in new-
borns had been prevented in the Netherlands due to the
annual screening.
Discussion
Participation rates in HIV screening among pregnant
women in the Netherlands are very high compared to
other EU countries (99.8%), due to the opting out princi-
ple [13-15]. For 40% of the pregnant women infected
with HIV the diagnosis was made for the first time dur-
ing pregnancy. The number of vertical HIV transmissions
Table 2 Results of blood tests for HIV, HBV and syphilis and the estimated number of prevented congenital infections
per year, 2006-2008
HIV HBV Syphilis
Positive diagnoses in pregnancies
2005/’06*† 57 545 142
congenital infections in 2006 130
2006/’07* 85 669 143
congenital infections in 2007 015
2007/’08* 86 633 105
congenital infections in 2008 011
Average number of diagnoses in pregnancy per year (2006-2007)* 75 615 130
Through screening newly diagnosed HIV, HBV or active syphilis per year, as percentage of the total screen-positives*‡§ 40% 40% 17%
Prevented children ‘at risk’ per year* 30 245 20
Transmission risk 20-30% 20-30% 50%
Estimated number of congenital infections prevented per year*|| 5-10 50-75 ± 10
*Minimum number, based on confirmed test results only
† Source: TNO-rapport 2008.
‡Sources: Stichting HIV Monitoring SHM (HIV), Osiris (HBV) and ‘Research voor beleid ‘ - Research for policy (syphilis).
§ Estimate of the number of active syphilis infections [5]
|| Estimate based on the average transmission risk of mother to child (in the absence of treatment and/or vaccination) and the estimate of the number of new
diagnoses (HIV/HBV) or active infection (syphilis) (based on women with a confirmed result)
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Figure 4 Number of test requests for congenital syphilis for neonates and young children (< 1 year) and the number of children
testing positive (IgM positive), 1997-2008 (source: RIVM, LIS).
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Page 5 of 7has decreased significantly, after the introduction of HIV
screening in 2004, to an average of 1 per year. At least 5
to 10 HIV infections were prevented in newborns
annually due to the screening programme. For syphilis
and HBV, the estimated numbers were 10 and 50-75.
HIV and syphilis infections, which were nevertheless
diagnosed in newborns, mainly concerned children of
mothers who had either not attended monitoring (on
time) or had acquired the infection after the first trime-
ster of pregnancy. Three of the five children born with
HBV had mothers who were highly infectious. Perinatal
transmission can still occur in pregnant women with a
high viral load, despite vaccination of newborns. While
HBeAg is an important marker for infectivity, ideally, for
every HBsAg-positive mother a viral load determination
should be made, since it is possible to have a high viral
load without being HBeAg positive [16]. Treatment with
antiviral agents is considered for these women, and can
improve the effectiveness of the screening programme
[17].
Only estimated prevalences could be derived for the
three infectious diseases due to missing or difficult to
interpret test results in Praeventis. There are strong indica-
tions that the number of registered syphilis infections in
pregnant women is an overestimation of the number of
cases of infectious syphilis. This is a result of false-positive
results (through endemic treponematoses) or previously
treated infections giving a positive result. At individual
level there was insufficient information about which test
had been carried out (VDRL or TPHA), which meant no
distinction could be made between active syphilis and a
previous case of syphilis. Data from a previous process eva-
luation [6] were used in order to calculate the number of
CS infection prevented by screening. For this calculation,
the midwives and gynaecologists of some of the syphilis
positive women were asked whether there had been an
active infection, which appeared to be case for 17%.
Although data collection for the screening of pregnant
women has improved in 2008 in respect of previous years,
quality assurance standards need to improve further [18].
Follow-up questions regarding missing test results regu-
larly revealed that the confirmatory test had not been
undertaken as HIV or HBV infection had already been
diagnosed. This means that positive results may have been
missed given that this information was not always available
at an individual level. Therefore, we presented prevalences
as minimum and maximum estimates. In 2009 a mini-
mum data set was implemented in Praeventis for preg-
nancy screening [18]. Following this, more comprehensive
background details will become available regarding newly
diagnosed and known carriers.
The screening programme takes place relatively early in
the pregnancy. Infections in pregnancy which are acquired
after screening go undetected. In our research period
infections such as these led to at least one perinatal HIV
transmission. However, screening later on in the preg-
nancy is not effective, as maternal treatment needs to be
started early (in the first trimester for syphilis). A second
screening late in pregnancy is highly unlikely to be cost-
effective as the incidence of HIV, HBV and syphilis infec-
tions in the Netherlands is low. This may be indicative, for
example in case of a known HIV-positive partner. Advice
on safe sex by the obstetric care is also important.
Prenatal screening provides a favourable cost-benefit
ratio even in low-endemic countries [19,20]. Studies in
Amsterdam showed that a universal screening programme
is cost-effective where HIV prevalence is 5 in 10,000
(0.05%) [19,20]. The benefit of universal screening is that
HIV, HBV, or syphilis positive women are detected who
do not fall into a known risk profile. Due to the fact that
infected women who are pregnant are being referred for
treatment their clinical prognosis will improve and the
risk of secondary transmission can be reduced. Universal
screening is considered simpler and more acceptable than
a programme only focused on risk groups.
Conclusions
We conclude that the screening programme in the
Netherlands is effective in detecting HIV, HBV and
syphilis in pregnant women and in preventing transmis-
sion to the child.
Based on cost effectiveness studies in the Netherlands
and other European countries, we conclude that antena-
tal screening is also cost effective [21]. More research is
required into the background characteristics of pregnant
women attending late or refusing HIV testing, as well as
the desirability of re-testing high-risk women just prior
to birth and those women with an unknown HIV status.
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